AbbVie Inc.: Number of Employees 2010-2024 | ABBV
Interactive chart of AbbVie Inc. (ABBV) annual worldwide employee count from 2010 to 2024.
- AbbVie Inc. total number of employees in 2024 was 55,000, a 10% increase from 2023.
- AbbVie Inc. total number of employees in 2023 was 50,000, a 0% decline from 2022.
- AbbVie Inc. total number of employees in 2022 was 50,000, a 0% decline from 2021.
- AbbVie Inc. total number of employees in 2021 was 50,000, a 6.38% increase from 2020.
| AbbVie Inc. Annual Employee Count |
| 2024 |
55,000 |
| 2023 |
50,000 |
| 2022 |
50,000 |
| 2021 |
50,000 |
| 2020 |
47,000 |
| 2019 |
30,000 |
| 2018 |
30,000 |
| 2017 |
29,000 |
| 2016 |
30,000 |
| 2015 |
28,000 |
| 2014 |
26,000 |
| 2013 |
25,000 |
| 2012 |
21,500 |
| 2011 |
21,000 |
| 2010 |
|
| 2009 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharma |
$356.743B |
$56.334B |
|
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
|
